


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:45Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406884" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406884</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406884</article-id><article-id pub-id-type="pmcid-ver">PMC12406884.1</article-id><article-id pub-id-type="pmcaid">12406884</article-id><article-id pub-id-type="pmcaiid">12406884</article-id><article-id pub-id-type="pmid">40889979</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2024-092110</article-id><article-id pub-id-type="publisher-id">bmjopen-2024-092110</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Protocol</subject></subj-group><subj-group subj-group-type="heading"><subject>Obstetrics and Gynaecology</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1845</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Development and validation of a dynamic prediction model for single-dose methotrexate treatment success in tubal ectopic pregnancy: a multicentre cohort study in Chinese hospitals</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-2098-1419</contrib-id><name name-style="western"><surname>Hu</surname><given-names initials="Y">Yunyun</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yao</surname><given-names initials="Z">Zhitao</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deng</surname><given-names initials="L">Liyun</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guan</surname><given-names initials="Q">Qinghong</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xinyan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor2" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Department of Gynaecology and Obstetrics</institution>, <institution>The First Affiliated Hospital of Zhejiang Chinese Medical University</institution>, <addr-line content-type="city">Hangzhou</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Obstetrics</institution>, <institution>Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University</institution>, <addr-line content-type="city">Hangzhou</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Gynaecology and Obstetrics, Affiliated Anji Branch Hospital</institution>, <institution>The First Affiliated Hospital of Zhejiang Chinese Medical University</institution>, <addr-line content-type="city">Huzhou</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff><aff id="aff4"><label>4</label><institution content-type="department">Department of Gynaecology and Obstetrics, Affiliated Qingyuan Branch Hospital</institution>, <institution>The First Affiliated Hospital of Zhejiang Chinese Medical University</institution>, <addr-line content-type="city">Qingyuan</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff></contrib-group><author-notes><corresp id="cor1">Dr Yunyun Hu; <email xlink:href="20173613@zcmu.edu.cn">20173613@zcmu.edu.cn</email></corresp><corresp id="cor2">Dr Xinyan Wang; <email xlink:href="13989843487@163.com">13989843487@163.com</email></corresp><fn fn-type="COI-statement" id="fn4"><p>None declared.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496158</issue-id><elocation-id>e092110</elocation-id><history><date date-type="received"><day>06</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-9.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-9.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Tubal ectopic pregnancy (TEP) frequently presents as a gynaecological emergency, often necessitating prompt medical intervention. Although methotrexate therapy offers the advantage of being non-invasive, it still poses the risk of tubal rupture and consequent haemorrhage, which may require emergency surgery. The major challenges encountered in practice are the lack of reliable methods to anticipate the likelihood of failure of single-dose methotrexate therapy and identify associated risk factors and thereby preclude unnecessary medical procedures. Effective counselling, therefore, remains a pivotal step in clinical management. This study is aimed at developing a predictive model to assess response to single-dose methotrexate therapy in cases of TEP by employing a dynamic prediction model approach based on the clinical data of a large cohort.</p></sec><sec><title>Methods and analysis</title><p>This multicentre study will encompass 100 and 900 participants for the prospective and retrospective cohorts with TEP, respectively. Between 2010 and 2024, eligible patients who are diagnosed with TEP and opt for single-dose methotrexate therapy will be recruited as part of a retrospective cohort, from three participating hospitals in Zhejiang province, China. The comprehensive medical and obstetric histories of the patients will be collected, along with their clinical data, including the results of serological tests following the initial consultation. The control group will comprise patients who achieve uneventful, complete resolution of TEP, as evidenced by serum human chorionic gonadotropin level of &lt;5&#8201;IU/L, without necessitating further treatment. The case group will include individuals requiring additional medical (further methotrexate) or surgical interventions. The dynamic prediction model developed in this manner will be employed on the longitudinal data. Additionally, data will be collected from two other hospitals between 2024 and 2026, as an external prospective cohort to validate the accuracy of the prediction model.</p></sec><sec><title>Ethics and dissemination</title><p>Ethical approval for data collection has been obtained from the Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (No. 2024-KLS-346&#8211;02), Hangzhou First People&#8217;s Hospital (No. ZN-20240627-0219-01), Anji Hospital of Chinese Medicine (No. 2025&#24180;&#31532;5&#21495;), Qingyuan Hospital of Chinese Medicine (No. (2024)&#20262;&#23457;&#31532;(9)&#21495;) and Beilun Hospital of Chinese Medicine (No. 2024&#24180;&#20262;&#23457;&#31532;12&#21495;). Additionally, written informed consent will be obtained from all participants and they will retain the right to withdraw from the study at any stage. The findings of this study will be disseminated through publication in a peer-reviewed journal.</p></sec><sec><title>Trial registration number</title><p>ChiCTR2400085829.</p></sec></abstract><kwd-group><kwd>Drug Therapy</kwd><kwd>Pregnancy</kwd><kwd>Pregnant Women</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Zhejiang Province Health Commission Science and Technology Project</institution></institution-wrap></funding-source><award-id>2023KY137</award-id></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Zhejiang Province Traditional Chinese Medicine Science and technology Project</institution></institution-wrap></funding-source><award-id>2023ZL048</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>In this study, we adopted a multicentre cohort design that integrates prospective and retrospective approaches.</p></list-item><list-item><p>Multivariate regression with mixed effects was used to build a dynamic model, which has been regarded as an ideal tool for processing longitudinal clinical data and achieving better accuracy.</p></list-item><list-item><p>A large multicentre, hospital-based prospective and retrospective cohort study will strengthen the robustness of our machine learning model by ensuring population diversity and minimising the selection bias.</p></list-item><list-item><p>Due to the limitation of resources, this study will be conducted only in hospitals located in Zhejiang.</p></list-item><list-item><p>The retrospective cohort could be prone to missing data or follow-up.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Ectopic pregnancy (EP)<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> is a condition in which embryo implantation occurs outside the uterine cavity,<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> with fallopian tubes being the site of implantation in almost 98% of the cases.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> EP is one of the most common gynaecological entities, affecting 2&#8211;3% of all pregnancies<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> and is responsible for 6% of all pregnancy-related deaths.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Management of EP mainly involves expectant management, surgery (such as salpingectomy or salpingostomy), or medical therapy with methotrexate (MTX). Although surgical treatment has been found to be effective, it carries risks such as infection, surgical trauma and trophoblastic persistence and entails higher costs. Approximately 25&#8211;30% of patients with EP are eligible for medical management with MTX.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Patients with early tubal pregnancies, if haemodynamically stable and without suspected tubal rupture, can be effectively managed with MTX. MTX has been found to be more cost-effective than surgical management and also offers the advantage of preserving fertility.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> The success rates of MTX treatment have been reported to range between 69% and 92.6%.<xref rid="R2" ref-type="bibr">27</xref><xref rid="R10" ref-type="bibr">10</xref> However, approximately 15% of the patients receiving single-dose MTX require rescue surgery.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Thus, a careful appraisal of risks is essential to counsel patients accordingly and offer the most suitable treatment option and thereby avoid secondary surgical intervention.</p><p>Hitherto, studies have predominantly focused on identifying risk factors associated with the medical treatment of tubal EP (TEP). For instance, Mackenzie <italic toggle="yes">et al</italic><xref rid="R1" ref-type="bibr"><sup>1</sup></xref> have shown that any decline in serum human chorionic gonadotropin (hCG) levels on Days 1&#8211;4 signified treatment success for women with TEP (initial hCG of &#8805;1000&#8201;and &lt;5000&#8201;IU/L) managed with single-dose MTX. Similarly, Kirk <italic toggle="yes">et al</italic><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> have shown that both a pretreatment serum hCG ratio (hCG 48 hours/hCG 0&#8201;hours) of &#8805;0.8&#8201;and a history of EP correlated with the failure of medical management. However, the investigation so far has predominantly focused on the factors influencing treatment outcomes, with less exploration into any predictive model. Furthermore, the primary statistical method employed in published studies is logistic regression, without the use of an independent validation cohort.</p><p>Thus, there is an unmet need for a validated prediction model that incorporates relevant factors to give clinicians individualised estimates of probability of single-dose MTX treatment success for the patients with TEP. The long-term goal of our study is to develop and validate a dynamic prediction model that uses longitudinal clinical data to address critical decision points in single-dose MTX management of EP. The model will provide:</p><list list-type="order" list-content="ol"><list-item><p>Incidence of treatment failure at the current time point: Measuring a patient&#8217;s risk of failing treatment at the moment by applying all information collected up to that exact point (eg, day-specific serum hCG trajectory, ultrasound findings, clinical symptoms).</p></list-item><list-item><p>Prospective risk projection: Generating personalised forecasts of failure probability at predefined clinical milestones (eg, Day 4 and Day 7 post-MTX administration).</p></list-item></list><p>Through iterative model recalibration triggered by new biomarker measurements (eg, updated serum hCG values), the system will dynamically update risk estimates both for the present state and future time horizons. These outputs will be integrated into a web-based clinical dashboard as actionable clinical alerts, delivering time-sensitive decision support of critical laboratory results. This framework bridges predictive analytics and clinical workflow to optimise intervention timing&#8212;reducing unnecessary procedures while preventing treatment delays.</p></sec><sec id="s2"><title>Methods and analysis</title><sec id="s2-1"><title>Study design and setting</title><p>This study is designed as a multicentre, hospital-based prospective and retrospective cohort study conducted across five hospitals in Zhejiang province, China. The anticipated duration of the study is 2 years (<xref rid="F1" ref-type="fig">figure 1</xref>). This study intends to allocate samples from the retrospective cohort of three hospitals into a training cohort, comprising 80% of the total samples, and the remaining 20% as an internal validation cohort. Samples from the remaining two hospitals will serve as the prospective cohort for independent external validation. This design allows for robust training and validation of the prediction model across multiple hospital settings, thereby enhancing its generalisability and reliability.</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Schematic diagram of study design. hCG, human chorionic gonadotropin; MTX, methotrexate; TEP, tubal ectopic pregnancy.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g001.jpg"/></fig></sec><sec id="s2-2"><title>Participants</title><p>We aim to recruit women diagnosed with EP, from clinics and gynaecology wards during the period between May 2024 and May 2026. The eligible participants will include pregnant women visiting the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou First People&#8217;s Hospital, Anji Hospital of Chinese Medicine, Beilun Hospital of Chinese Medicine or Qingyuan Hospital of Chinese Medicine. Among the five centres, the First Affiliated Hospital of Zhejiang Chinese Medical University serves as the coordinating centre.</p><p>The inclusion criteria are as follows: (1) presentation with vaginal bleeding or pelvic pain during early pregnancy; (2) serum hCG values of &lt;4500&#8201;IU/L; (3) transvaginal ultrasound revealing TEP, excluding intrauterine pregnancy (serial serum hCG measurements will be conducted if the pregnancy type is unclear); (4) presence of an unruptured mass and stable haemodynamics; and (5) choice of medical management with MTX as a single-dose intramuscular injection (50 mg/m<sup>2</sup>) following communication of precautions and under close monitoring.</p><p>The following patient groups will be excluded from the study: (1) haemodynamically unstable patients; (2) patients preferring surgical or expectant management; (3) patients diagnosed with non-tubal pregnancy; and (4) patients with absolute contraindications to MTX treatment, including those with intrauterine pregnancy, immunodeficiency, anaemia, leucopenia, thrombocytopenia, MTX allergy, renal or hepatic insufficiency, pulmonary disease, active peptic ulcer disease, coinciding intrauterine pregnancy, breastfeeding or fetal cardiac activity.</p><p>The eligible women will be invited by the researchers to participate, provided with an explanation of the study protocol and aims, and enrolled in the study once they sign the informed consent form. Additionally, patients who visited and received MTX treatment in the participating clinics between 2010 and 2024 will be included retrospectively.</p></sec><sec id="s2-3"><title>Sample size and power analysis</title><p>Based on the events per variable (EPV) principle,<xref rid="R13" ref-type="bibr"><sup>13 14</sup></xref> this study requires 260 events for model development with 13 df at EPV=20. Given the 20% of single-dose MTX failure,<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> this translates to 1300 participants. Accounting for a 10% drop-out rate, 1445 patients will be enrolled.</p><p>The minimum sample size was calculated using Riley&#8217;s method<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> for prediction model development via the &#8216;pmsampsize&#8217; package in R. The &#8216;pmsampsize&#8217; package (parameters: Cox-Snell R&#178;=0.052, daily event rate=0.0067, mean follow-up=30&#8201;days, prediction time point=7&#8201;days, 13 candidate parameters, shrinkage=0.90) independently confirmed this requirement. After a 10% drop-out adjustment, the final target enrolment is 2427 patients to ensure robust model development and adequate statistical power for validation.</p><p>Evidence suggests that to achieve 80% statistical power and an alpha of 0.05 for external validation, at least 100 positive and 100 negative cases are needed.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> According to the preliminary trial data, more than half of the surgeries or repeat MTX treatments occur between days 7 and 10. Due to a 10% failure rate and 15% dropout rate typically observed on Day 7, we estimate that 1176 patients will need to participate. This sample size ensures adequate events across time points.</p><p>With a total of 2427 development and 1176 validation samples, the cohort size will ensure adequate statistical power for both the model development and validation phases.</p></sec><sec id="s2-4"><title>Outcomes and measures</title><p>The primary outcome of this study is single-dose MTX treatment failure, defined as the requirement for additional medical intervention (further MTX doses) or surgical intervention (salpingectomy or salpingostomy, performed via laparoscopy or laparotomy). Conversely, successful treatment is defined as the complete solution of the EP without requiring any further MTX doses or surgical intervention, which is also jointly confirmed by both a decline in serum hCG levels to &lt;5&#8201;IU/L and a disappearance of any associated adnexal mass. The decision to proceed with additional intervention (either further MTX therapy or surgery) will be made jointly by the attending clinician and the participant based on clinical judgement. This judgement incorporates factors such as worsening clinical symptoms, increasing or plateauing serum hCG levels, clinical, laboratory and/or ultrasound evidence of intra-abdominal bleeding, or the participant&#8217;s request for surgery.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> The overall technical protocol for patient management, including criteria for intervention and outcome assessment, is detailed in <xref rid="F2" ref-type="fig">figure 2</xref>.</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Technical protocol of this study. TEP, tubal ectopic pregnancy.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g002.jpg"/></fig></sec><sec id="s2-5"><title>Data collection</title><p>Data will be collected using a customised case report form including participant demographics, general medical history, clinical signs/symptoms, EP diagnostic details and treatment information (<xref rid="T1" ref-type="table">table 1</xref>). The researchers can extract data from the hospital&#8217;s medical record system.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Data collection form</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="top" colspan="2" rowspan="1">Admission date: ______</td><td align="left" valign="top" colspan="2" rowspan="1">Discharge date: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Name: ______</td><td colspan="2" align="left" valign="top" rowspan="1">Age (years):______</td><td align="left" valign="top" rowspan="1" colspan="1">Identification number: ______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Nationality: &#9744;Han &#9744;Hui &#9744;Zang &#9744;Yi &#9744;Wei &#9744;Others: ______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Current residence: &#9744;City &#9744;Town &#9744;Rural</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Occupation: &#9744;Professional technicians (&#9744;Medical &#9744;Others) &#9744;Civil servant &#9744;Ordinary staff &#9744;Farmer &#9744;Worker &#9744;Businessman &#9744;Teacher &#9744;Lawyer &#9744;Others:______</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Smoking: &#9744;Yes &#9744;No</td><td colspan="2" align="left" valign="top" rowspan="1">Drink alcohol: &#9744;Yes &#9744;No</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Menopause (days): _______</td><td colspan="2" align="left" valign="top" rowspan="1">Abdominal pain (days): _______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Vaginal bleeding (days): _______</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Last menstrual period (date): _______</td><td colspan="2" align="left" valign="top" rowspan="1">Previous menstrual period (date): _______</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Number of pregnancies (including this pregnancy): ______</td><td colspan="2" align="left" valign="top" rowspan="1">Parity (including this delivery): ______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Mode of last deliveries (if applicable): &#9744;Elective caesarean section &#9744;Vaginal delivery</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Height: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg) :______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Other diseases: &#9744;None &#9744;Acquired Immune Deficiency Syndrome &#9744;Syphilis &#9744;Hepatitis A &#9744;Hepatitis B &#9744;Hepatitis C &#9744;Others: ______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Results of laboratory test:</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td colspan="2" align="left" valign="top" rowspan="1">White blood cell (&#215;10<sup>9</sup>/L): ______</td><td align="left" valign="top" rowspan="1" colspan="1">Total lymphocyte count (&#215;10<sup>9</sup>/L): ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1">Blood platelet (&#215;10<sup>9</sup>/&#8201;L): ______</td><td align="left" valign="top" rowspan="1" colspan="1">Neutrophils: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1">Red blood cell (&#215;10<sup>12</sup>/L): ______</td><td align="left" valign="top" rowspan="1" colspan="1">Haemoglobin (g/L): ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td align="left" valign="top" rowspan="1" colspan="1">&#914;-hCG: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Estradiol: ______</td><td align="left" valign="top" rowspan="1" colspan="1">Progesterone: ______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">B-ultrasound test&#65306;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td colspan="2" align="left" valign="top" rowspan="1">Ectopic mass size: _____&#215;_____&#215;____cm</td><td align="left" valign="top" rowspan="1" colspan="1">Pelvic effusion: _____&#215;_____&#215;____cm</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td colspan="2" align="left" valign="top" rowspan="1">Ectopic mass size: _____&#215;_____&#215;____cm</td><td align="left" valign="top" rowspan="1" colspan="1">Pelvic effusion: _____&#215;_____&#215;____cm</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">_________(yy/mm/dd)</td><td colspan="2" align="left" valign="top" rowspan="1">Ectopic mass size: _____&#215;_____&#215;____cm</td><td align="left" valign="top" rowspan="1" colspan="1">Pelvic effusion: _____&#215;_____&#215;____cm</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Group: &#9744;0=succeed in single-dose MTX therapy &#9744;1=failed in single-dose MTX therapy</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Time of surgical intervention (yy/mm/dd): ______</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Time of using MTX (yy/mm/dd): ______</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>B-hCG, beta human chorionic gonadotropin; MTX, methotrexate.</p></fn></table-wrap-foot></table-wrap><p>Participants in the prospective cohort will be provided with an informed consent form, to request permission for accessing their medical records for this study. The consent form will state that participation is voluntary and participants retain the right to withdraw at any time without consequences to their care. Data will be collected during the initial intake visit and stored securely in the electronic data capture software &#8216;Epidata&#8217;. Participants of the prospective cohort will be followed up until either surgical intervention (salpingectomy or salpingostomy) occurs or, in the absence of surgery, until serum hCG levels drop to &lt;5&#8201;IU/L and the associated adnexal mass disappears. Retrospective cohort participants will undergo regular visits or telephone follow-ups to assess outcomes.</p></sec><sec id="s2-6"><title>Statistics analysis</title><p>The primary endpoint is MTX treatment failure, defined as the requirement for additional medical (further MTX) or surgical intervention. Participants not undergoing surgery will be followed until confirmed biochemical resolution (serum hCG &lt;5&#8201;IU/L) and sonographic disappearance of the associated adnexal mass.</p><p>Missing data will be systematically identified, and their reasons and potential mechanisms assessed. Individuals missing all longitudinal biomarker observations (serum hCG, estradiol, progesterone) will be excluded from the analysis, as the dynamic prediction model requires at least one time-point measurement. For individuals with partial missing data in predictor variables or covariates, multiple imputation techniques under the assumption of missing at random will be employed to create multiple imputed datasets. Prior to analysis and model building, raw values of the longitudinal biomarkers (serum hCG, estradiol, progesterone) will undergo log<sub>10</sub> transformation to approximate normality.</p><p>Continuous variables will be described as mean&#177;SD&#8201;or median, and the Mann-Whitney U test and t-test will be used to identify the differences between the case group and the control group. Categorical variables will be represented as numbers and percentages (%), and Pearson&#8217;s &#967;<sup>2</sup> and Fisher&#8217;s exact probability test will be used to identify intergroup differences.</p><p>Statistical analyses will be performed using IBM SPSS Statistics V.15.0, and R V.4.3.2. A two-tailed p&lt;0.05&#8201;will be considered statistically significant.</p></sec><sec id="s2-7"><title>Dynamic model development and internal validation</title><p>The model generates an updated risk score (0&#8211;100%) for MTX failure, integrating baseline variables (eg, initial hCG, gestational age) and time-dependent biomarkers (serial hCG, progesterone). The model generates a rolling risk score updated at predefined time points during treatment (Days 0, 4 and 7 post-MTX administration, or symptoms change, such as worsening abdominal pain). Time 0 is defined as the time of MTX administration.</p><p>Treatment success and failure were prospectively defined per international consensus guidelines,<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> with critical evaluations anchored to fixed post-MTX time points:</p><p>At Day 4: Failure risk was flagged if serum hCG declined by &lt;15% from baseline (Day 0)<xref rid="R1" ref-type="bibr"><sup>1</sup></xref>.</p><p>At Day 7: Treatment was deemed unsuccessful if either: (1) serum hCG plateaued (consecutive measurements changing &lt;&#177;15%) or rebounded, or (2) clinical rupture signs emerged (haemodynamic instability, worsening pain or haemoperitoneum).<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Success required serum hCG decline to non-pregnant levels (&lt;5&#8201;IU/L) without intervention. Patients undergoing surgery before Day 7 were recorded as failures at the event date.</p><p>In addition to these time-to-event predictions, we developed a longitudinally adaptive predictor that updates the risk at every clinical intervention opportunity (Day 0/4/7 and weekly thereafter). Our predictor takes temporal predictors, such as change in serum hCG rate (&#916;hCG/&#916;t), absolute thresholds and symptom progression as inputs. In addition to providing real-time stratification of the current failure risk, it projects the risk for subsequent time points (eg, 4&#8201;days, 7&#8201;days) at each update. When new serum hCG results come in, risk tiers&#8212;low, intermediate and high&#8212;get sent to the web-based clinical dashboard. Along with these results, we overlay visual trend graphs that specifically highlight intervention thresholds during key monitoring periods. This way, the dashboard not only displays risk levels in real time but also uses visual cues to draw attention to critical points where clinical action might be needed.</p><p>The cohort of 2427 patients with suspected EP was stratified by age and clinical risk factors; the dataset was divided into 80% training set and 20% internal validation set. The predictive features were screened using univariate analysis and then via LASSO (Least Absolute Shrinkage and Selection Operator) regression (GLMnet implementation) and later they were finalised by clinical knowledge and experts&#8217; advice. The mixed effect model (R package &#8216;merlin&#8217;) and the following three machine learning models (Deep Neural Network, Random Forest and GLMnet) will be used to build and validate the models. Models were trained using repeated three times fivefold cross-validation for hyperparameter tuning. The internal validation used bootstrap resampling (500 iterations) in order to estimate the optimism. Performance was measured using discrimination (AUC, Area Under the Receiver Operating Characteristic Curve, with 95%&#8201;CI), calibration curves and clinical decision curve analysis for all four approaches.</p><p>Following model development, a web-based clinical dashboard will be implemented to operationalise dynamic risk prediction in real-world practice.</p></sec><sec id="s2-8"><title>Model prospective external cohort validation</title><p>The finalised model including the set of variables, coefficients and algorithmic code resulting from the retrospective cohort will be fixed in a preregistered Statistical Analysis Plan before prospective validation. When predicting Day 7 failure, we rely on two distinct criteria. First, for predictions updated with Day 4 data, we require an AUC &#8805;0.80 (with a 95%&#8201;CI lower bound &#8805;0.70) to ensure reliable discrimination between outcomes. Additionally, the model must pass calibration checks: a Hosmer-Lemeshow p value &gt;0.05&#8201;and &lt;5% deviation from perfect prediction to ensure clinical utility. Second, the ultimate Day 7 prediction must achieve &#8805;90% sensitivity, &#8804;10% false positives and rigorous validation against real-world outcomes to balance accuracy and practicality. Ultimate integrity will be maintained through the application of a locked code structure implemented on a dedicated web-based application. To maintain objectivity, our platform strictly separates roles: clinical staff input serial biomarker measurements and record final treatment outcomes without seeing the model&#8217;s risk predictions, while statisticians analyse validation datasets kept entirely separate from clinical inputs and intermediate calculations. This dual-process design ensures unbiased data collection and rigorous statistical validation.</p><p>A Bayesian interim analysis will be conducted at 30% and 60% of the planned sample size (1176) to re-evaluate sample size requirements. Using predictive probability (PredP) and posterior probability (PostP), we will assess the stability of data and the probability of meeting predefined equivalence criteria (model failure rate difference &#8804;5%). The prior distribution will be updated with observed data to compute PostP of equivalence and PredP for future outcomes. If PredP &#8805;0.99, the trial may stop early; if PredP &#8804;0.10, it will terminate for futility.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p><p>Although the external validation cohort target of 100 failure events may appear limited, this meets the minimum requirement of 100 events for model validation as per Vergouwe <italic toggle="yes">et al</italic>.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Interim Bayesian analyses at 30% and 60% enrolment will allow early termination if predictive performance stabilises, ensuring statistical rigour while addressing pragmatic constraints in prospective recruitment.</p></sec><sec id="s2-9"><title>Model reporting and interpretation</title><p>After validation and comparison of the four machine learning (DNN, Deep Neural Network; RF, Random Forest; GLMnet, Merlin) models, the most suitable model in terms of integrated discrimination, clinical utility and calibration stability will be chosen as the model for prediction of the success of MTX single-dose therapy in EP. This final model will be comprehensively reported in adherence to the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statement.</p></sec><sec id="s2-10"><title>Patient and public involvement</title><p>Neither patients nor the public was involved in the design, conduct, reporting or dissemination plans of our research.</p></sec></sec><sec id="s3"><title>Ethics and dissemination</title><p>This study will be conducted in accordance with the principles of the Declaration of Helsinki. The ethical approval for this study was obtained from all participating hospitals, including the Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (No. 2024-KLS-346&#8211;02; email: szyyky@163.com), Hangzhou First People&#8217;s Hospital (No. ZN-20240627-0219-01; email: 1742208034@qq.com), Anji Hospital of Chinese Medicine (No. 2025&#24180;&#31532;5&#21495;; email: ajzyy@hotmail.com), Qingyuan Hospital of Chinese Medicine (No. (2024)&#20262;&#23457;&#31532;(9)&#21495;; email: 40983285@qq.com), and Beilun Hospital of Chinese Medicine (No. 2024&#24180;&#20262;&#23457;&#31532;12&#21495;; email: blxqyy@163.com). There are no risks or burdens associated with participation in this study. Informed consent will be obtained from all participants in the prospective cohort. In addition, data will be collected during regular hospital visits or via telephonic follow-up interviews. All methods will be executed in accordance with the relevant guidelines and regulations. Written informed consent will be obtained from all participants, and they will have the right to withdraw from the study at any time. For retrospective participants, informed consent was obtained via reserved contact information (phone/email), while for unreachable subjects, the Ethics Committee waived individual consent requirements given the anonymised use of existing clinical data. The findings of this study will be disseminated through peer-reviewed publications and presentations at international conferences.</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This study is aimed at constructing a prediction model for the response to MTX therapy in TEP using dynamic prediction model. Previous research has been focused on exploring factors associated with failure risk in MTX treatment for TEP. As a step further, we believe that our findings will contribute to reducing the need for secondary surgery. Our study has several merits. First, it is a multicentre cohort study. Unlike previous prediction models that were based on single-centre retrospective studies, a model based on a multicentre cohort study can minimise geographical differences, increase subject diversity and enhance statistical effectiveness.</p><p>Second, we will focus on the relationship between the time of menstrual cessation and dynamic changes in serum hCG. Previous studies have shown that higher initial serum hCG levels and a pretreatment serum hCG ratio (hCG 48 hours/hCG 0&#8201;hours) of &#8805;0.8&#8201;are related to lower success rates in patients.<xref rid="R12" ref-type="bibr"><sup>12 16 18</sup></xref> Additionally, a fall or only a modest (&lt;18%) rise on Days 1&#8211;4 serum hCG signified an 82&#8211;85% likelihood of single-dose MTX treatment success for women with TEP.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> However, previous studies did not control for the influence of factors such as menolipsis and dynamic changes in serum hCG levels, which might reflect the trophoblast proliferation rate and help evaluate the treatment effect of MTX. In addition, we will use a dynamic prediction model to construct the model. The existing clinical prediction models primarily use static models (mainly logistic or Cox)<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> that use cross-sectional data collected at the baseline time point, t<sub>0</sub>. Therefore, these models do not take into consideration changes in indicators during the disease progression process (repeated measurements data from time<sub>1</sub> to time<sub>n</sub>, cov<sub>1</sub> to cov<sub>n</sub> and so on), leading to reduced accuracy in outcome predictions.<xref rid="R20" ref-type="bibr">20</xref><xref rid="R22" ref-type="bibr">22</xref> To address this limitation, we intend to establish a dynamic prediction model based on the updated measurements of serum hCG for use in the evaluation of treatment efficacy.</p><p>The ultimate goal of this study is to accurately predict the outcomes of MTX therapy in patients with TEP, thereby enabling the early identification and intervention for risk factors and allowing for counselling of patients to choose appropriate treatment plans. The outcomes of this study will provide tailored and individual prognostic assessments of MTX therapy in TEP, which will need to be validated externally to ensure generalisability. Due to resource limitations, this study will only be conducted in hospitals in Zhejiang, which may reduce the population diversity. To address the limitation of generalisability, we plan to deploy a web-based calculator (Shiny app) after model development and internal validation. This tool will enable real-time data input from clinicians across broader geographical regions in China, facilitating prospective external validation of the prediction model in diverse patient populations and enhancing its clinical applicability.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This work was supported by grants from Zhejiang Province Health Commission Science and Technology Project (Grant No. 2023KY137) and Zhejiang Province Traditional Chinese Medicine Science and technology Project (Grant No. 2023ZL048).</p></fn><fn fn-type="other"><p><bold>Prepub:</bold> Prepublication history for this paper is available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2024-092110" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2024-092110</ext-link>).</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackenzie</surname><given-names>SC</given-names></name><name name-style="western"><surname>Moakes</surname><given-names>CA</given-names></name><name name-style="western"><surname>Doust</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>Early (Days 1-4) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancy</article-title><source><italic toggle="yes">Hum Reprod</italic></source><year>2023</year><volume>38</volume><fpage>1261</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/humrep/dead089</pub-id><pub-id pub-id-type="pmid">37178269</pub-id><pub-id pub-id-type="pmcid">PMC10320483</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirk</surname><given-names>E</given-names></name><name name-style="western"><surname>Papageorghiou</surname><given-names>AT</given-names></name><name name-style="western"><surname>Condous</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>The diagnostic effectiveness of an initial transvaginal scan in detecting ectopic pregnancy</article-title><source><italic toggle="yes">Hum Reprod</italic></source><year>2007</year><volume>22</volume><fpage>2824</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/humrep/dem283</pub-id><pub-id pub-id-type="pmid">17855406</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franasiak</surname><given-names>JM</given-names></name></person-group><article-title>ACOG Practice Bulletin No. 191 Summary: Tubal Ectopic Pregnancy</article-title><source>Obstet Gynecol</source><year>2018</year><volume>131</volume><fpage>409</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000002499</pub-id><pub-id pub-id-type="pmid">29370045</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panelli</surname><given-names>DM</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>CH</given-names></name><name name-style="western"><surname>Brady</surname><given-names>PC</given-names></name></person-group><article-title>Incidence, diagnosis and management of tubal and nontubal ectopic pregnancies: a review</article-title><source>Fertil Res Pract</source><year>2015</year><volume>1</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s40738-015-0008-z</pub-id><pub-id pub-id-type="pmid">28620520</pub-id><pub-id pub-id-type="pmcid">PMC5424401</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurkovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>H</given-names></name></person-group><article-title>Diagnosis and management of ectopic pregnancy</article-title><source>BMJ</source><year>2011</year><volume>342</volume><elocation-id>bmj.d3397</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.d3397</pub-id><pub-id pub-id-type="pmid">21665933</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourel</surname><given-names>G</given-names></name><name name-style="western"><surname>Pelletier-Fleury</surname><given-names>N</given-names></name><name name-style="western"><surname>Bouyer</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Cost-effectiveness analysis of medical management versus conservative surgery for early tubal pregnancy</article-title><source><italic toggle="yes">Hum Reprod</italic></source><year>2019</year><volume>34</volume><fpage>261</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/humrep/dey352</pub-id><pub-id pub-id-type="pmid">30520964</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alleyassin</surname><given-names>A</given-names></name><name name-style="western"><surname>Khademi</surname><given-names>A</given-names></name><name name-style="western"><surname>Aghahosseini</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Comparison of success rates in the medical management of ectopic pregnancy with single-dose and multiple-dose administration of methotrexate: a prospective, randomized clinical trial</article-title><source>Fertil Steril</source><year>2006</year><volume>85</volume><fpage>1661</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2005.11.055</pub-id><pub-id pub-id-type="pmid">16650421</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saadati</surname><given-names>N</given-names></name><name name-style="western"><surname>Najafian</surname><given-names>M</given-names></name><name name-style="western"><surname>Masihi</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Comparison of Two Different Protocols of Methotrexate Therapy in Medical Management of Ectopic Pregnancy</article-title><source>Iran Red Crescent Med J</source><year>2015</year><volume>17</volume><elocation-id>e20147</elocation-id><pub-id pub-id-type="doi">10.5812/ircmj.20147</pub-id><pub-id pub-id-type="pmid">26756008</pub-id><pub-id pub-id-type="pmcid">PMC4706730</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sowter</surname><given-names>MC</given-names></name><name name-style="western"><surname>Farquhar</surname><given-names>CM</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>KJ</given-names></name><etal>et al</etal></person-group><article-title>A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy</article-title><source>Br J Obstet Gynaecol</source><year>2001</year><volume>108</volume><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0306-5456(00)00038-3</pub-id><pub-id pub-id-type="pmid">11236120</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipscomb</surname><given-names>GH</given-names></name><name name-style="western"><surname>Givens</surname><given-names>VA</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>NL</given-names></name><etal>et al</etal></person-group><article-title>Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy</article-title><source>Fertil Steril</source><year>2004</year><volume>81</volume><fpage>1221</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2003.09.070</pub-id><pub-id pub-id-type="pmid">15136080</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ludlow</surname><given-names>JP</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Single-dose methotrexate treatment for ectopic pregnancy and pregnancy of unknown location and progesterone as a predictor of success</article-title><source>Aust N Z J Obstet Gynaecol</source><year>2014</year><volume>54</volume><fpage>469</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/ajo.12247</pub-id><pub-id pub-id-type="pmid">25287564</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirk</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Calster</surname><given-names>B</given-names></name><name name-style="western"><surname>Condous</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Ectopic pregnancy: using the hCG ratio to select women for expectant or medical management</article-title><source>Acta Obstet Gynecol Scand</source><year>2011</year><volume>90</volume><fpage>264</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0412.2010.01053.x</pub-id><pub-id pub-id-type="pmid">21306315</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>RD</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>J</given-names></name><name name-style="western"><surname>Snell</surname><given-names>KIE</given-names></name><etal>et al</etal></person-group><article-title>Calculating the sample size required for developing a clinical prediction model</article-title><source>BMJ</source><year>2020</year><volume>368</volume><elocation-id>m441</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m441</pub-id><pub-id pub-id-type="pmid">32188600</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>RD</given-names></name><name name-style="western"><surname>Snell</surname><given-names>KI</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes</article-title><source>Stat Med</source><year>2019</year><volume>38</volume><fpage>1276</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1002/sim.7992</pub-id><pub-id pub-id-type="pmid">30357870</pub-id><pub-id pub-id-type="pmcid">PMC6519266</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vergouwe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name><name name-style="western"><surname>Eijkemans</surname><given-names>MJC</given-names></name><etal>et al</etal></person-group><article-title>Substantial effective sample sizes were required for external validation studies of predictive logistic regression models</article-title><source>J Clin Epidemiol</source><year>2005</year><volume>58</volume><fpage>475</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2004.06.017</pub-id><pub-id pub-id-type="pmid">15845334</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Committee on Practice Bulletins&#8212;Gynecology</collab></person-group><article-title>ACOG Practice Bulletin No. 191: Tubal Ectopic Pregnancy</article-title><source>Obstet Gynecol</source><year>2018</year><volume>131</volume><fpage>e65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000002464</pub-id><pub-id pub-id-type="pmid">29232273</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>D</given-names></name><name name-style="western"><surname>Ludes</surname><given-names>P-O</given-names></name><name name-style="western"><surname>Diemunsch</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Bayesian predictive probabilities: a good way to monitor clinical trials</article-title><source>Br J Anaesth</source><year>2021</year><volume>126</volume><fpage>550</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2020.08.062</pub-id><pub-id pub-id-type="pmid">33129491</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Prine</surname><given-names>L</given-names></name></person-group><article-title>Ectopic Pregnancy: Diagnosis and Management</article-title><source>Am Fam Physician</source><year>2020</year><volume>101</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">32412215</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>LM</given-names></name><name name-style="western"><surname>Lunt</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>GP</given-names></name><etal>et al</etal></person-group><article-title>Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods</article-title><source>Diagn Progn Res</source><year>2020</year><volume>4</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/s41512-020-00078-z</pub-id><pub-id pub-id-type="pmid">32671229</pub-id><pub-id pub-id-type="pmcid">PMC7346415</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>GL</given-names></name><name name-style="western"><surname>Grant</surname><given-names>SW</given-names></name><name name-style="western"><surname>Caiado</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Dynamic prediction modeling approaches for cardiac surgery</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2013</year><volume>6</volume><fpage>649</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.111.000012</pub-id><pub-id pub-id-type="pmid">24150044</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizopoulos</surname><given-names>D</given-names></name><name name-style="western"><surname>Molenberghs</surname><given-names>G</given-names></name><name name-style="western"><surname>Lesaffre</surname><given-names>EMEH</given-names></name></person-group><article-title>Dynamic predictions with time&#8208;dependent covariates in survival analysis using joint modeling and landmarking</article-title><source>Biometrical J</source><year>2017</year><volume>59</volume><fpage>1261</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1002/bimj.201600238</pub-id><pub-id pub-id-type="pmid">28792080</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Moving beyond the Cox proportional hazards model in survival data analysis: a cervical cancer study</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><elocation-id>e033965</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2019-033965</pub-id><pub-id pub-id-type="pmcid">PMC7371360</pub-id><pub-id pub-id-type="pmid">32690495</pub-id></element-citation></ref></ref-list></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>01</day><month>09</month><year>2025</year></pub-date></front-stub><body><fig id="d67e1225" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2024-092110.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>